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Highlights 
 The pathophysiology of SCI are poorly understood. 
 Axonal and myelin sheath properties was changed as time elapsed from the injury. 
 The pathophysiology of axons and myelin sheath differ in various phases of SCI. 
 These changes are affected by multiple factors related to the injury. 
 
Abstract 
The pathophysiology of spinal cord injury (SCI) related processes of axonal degeneration and 
demyelination are poorly understood. The present systematic review and meta-analysis were 
performed such to establish quantitative results of animal studies regarding the role of injury 
severity, SCI models and level of injury on the pathophysiology of axon and myelin sheath 
degeneration. 39 related articles were included in the analysis. The compiled data showed that 
the total number of axons, number of myelinated axons, myelin sheath thickness, axonal 
conduction velocity, and internode length steadily decreased as time elapsed from the injury 
(Pfor trend<0.0001). The rate of axonal retrograde degeneration was affected by SCI model and 
severity of the injury.  Axonal degeneration was higher in injuries of the thoracic region. The SCI 
model and the site of the injury also affected axonal retrograde degeneration. The number of 
myelinated axons in the caudal region of the injury was significantly higher than the lesion site and 
the rostral region. The findings of the present meta-analysis show that the pathophysiology of 
axons and myelin sheath differ in various phases of SCI and are affected by multiple factors 
related to the injury.  
 
Keywords: Animal studies; Degeneration; Myelin sheath; Spinal cord injuries   
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1 Introduction: 
Events following spinal cord injury (SCI) are classified in three general phases of acute, sub-
acute and chronic (1). Pathophysiology of SCI recovery and reorganization are different in 
these three phases and lead to the manifestation of different clinical symptoms (2). Axonal 
degeneration is considered one of the major mechanisms of the degeneration process and 
occurs differently in each phase. Currently, the presence of axonal degeneration after spinal 
cord injury has been established and different treatments for neurologic injury have been 
implemented (3). Unfortunately, these treatments have not been effective in most cases. 
Some researchers believe that the creation of new rostral and caudal connections through the 
injury site with the induction of sprouting and axonal regeneration does not necessarily lead to 
improvement in sensory and motor functions but could lead to exacerbation of irritating 
syndromes such as neuropathic pain (4, 5). It is possible that this response is due to the process 
of axonal and myelin changes as a result of the injury. In addition, it has not fully addressed 
how the severity of the injury, SCI model, and level of injury (cervical, thoracic and 
thoracolumbar) affect the axonal and myelin pathophysiology. Further, does axonal 
degeneration status differ in rostral and caudal regions of the injury? Therefore, this systematic 
review and meta-analysis aim to gather existing quantitative animal findings in the field of axon 
and myelin sheath pathophysiology following SCI. 
2 Methods: 
2.1 Search strategy 
In this systematic review and meta-analysis, by using words related to SCI in combination with 
keywords related to pathophysiology, a search was done in Medline and Embase from 1946 
until December 2015. These articles were supplemented with a further search utilizing a 
Google search engine and Google scholar and the references of related articles. Keywords were 
selected based on Mesh and Emtree databases, using the titles of related articles, and 
consultation with experts. The search query in Medline and Embase databases has been shown 
in table 1. 
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Table 1: Search sterategies used in Medline and Embase 
Medline via PubMed EMBASE via Ovid SP 
("Spinal Cord Injuries/pathology"[Mesh] OR "Spinal 
Cord Injuries/physiopathology"[Mesh]) OR 
(((Trauma*[tiab] OR Injur*[tiab]) AND (Spinal[tiab] 
AND Cord[tiab])) AND (Pathophysiolog*[tiab] OR 
Physiopatholog*[tiab] OR Patholog*[tiab] OR 
Pathobiolog*[tiab] OR Histopatholog*[tiab])) AND 
("Time"[Mesh:NoExp] OR "Time Factors"[Mesh] OR 
"Chronology as Topic"[Mesh] OR "Acute 
Disease"[Mesh] OR Time[tiab] OR Timing[tiab] OR 
Chronolog*[tiab] OR Min[tiab] OR Minute*[tiab] 
OR Hour[tiab] OR Hours[tiab] OR Day[tiab] OR 
Days[tiab] OR Week*[tiab] OR Month*[tiab] OR 
Year*[tiab] OR Phase[tiab] OR Phases[tiab] OR 
Stage[tiab] OR Stages[tiab] OR Early[tiab] OR 
Late[tiab] OR Primary[tiab] OR Secondary[tiab] OR 
Acute[tiab] OR Subacute[tiab] OR Subchronic[tiab]) 
AND ("Animals"[Mesh]) 
1. spinal cord injury/ 
2. (Spinal adj Cord adj (Trauma$ or Injur$)).ti,ab. 
3. or/1-2 
4. exp pathology/ 
5. pathophysiology/ 
6. histopathology/ 
7. (Pathophysiolog$ or Physiopatholog$ or 
Patholog$ or Pathobiolog$ or Histopatholog$).ti,ab. 
8. or/4-7 
9. time/ 
10. chronology/ 
11. acute disease/ 
12. (Time or Timing or Chronolog$ or Min or 
Minute? or Hour? or Day? or Week? or Month? or 
Year? or Phase? or Stage? or Early or Late or Primary 
or Secondary or Acute or Subacute).ti,ab. 
13. or/9-12 
14. 3 and 8 and 13 
15. limit 14 to animals 
 
2.2 Inclusion criteria 
We included all animal studies in which axonal or myelin sheath pathophysiology was the main 
subject of the study. Exclusion criteria consisted of human studies, review articles and studies 
lacking quantitative report of the findings.  
2.3 Data extraction and the quality control 
A detailed review of the methodology of searching, screening, and summarizing articles is in 
our previous studies (6-13). In summary, two independent reviewers selected related articles 
based on the inclusion and exclusion criteria by reading the title and abstract and then the full 
text. A checklist was used to extract the related data of full papers. This checklist was designed 
based on the PRISMA Guideline. These variables included the name of the first author of the 
article, year of publication, the number of samples, species and genus of the animals, SCI model 
including compression injury, contusion (weight-drop apparatuses, electromagnetic 
impactors) model, crush injury, hemisection, and transection, as well as severity of injury, level 
of injury, tracer of axon and myelin, follow up durations and outcomes. Classification of injuries 
and determining injury severity was done based on the definition given in the article by 
AC
CE
PT
ED
 M
AN
US
CR
IPT
6 
 
Cheriyan et al. (14). In addition, duration of follow up was divided into three groups of 
immediate-acute, sub-acute, and chronic phases. 
In many articles, data were presented graphically. In these cases for extraction of data plot 
digitizer software version 2.0 was applied; a method that has higher accuracy and speed 
compared to the manual method (15). Finally, the quality control of the studies was performed 
according to the guidelines provided by Hassannejad et al. (16). 
2.4 Outcomes 
The outcomes in the present study were classified in six sections, including 1) total number of 
axons, 2) number of myelinated axons, 3) rate of axonal retrograde degeneration, 4) myelin 
sheath thickness based on G-ratio (inner region of axon/total thickness of axon including 
myelin sheath), 5) internode length (distance between adjacent Ranvier nodes), and 6) axon 
conduction velocity. The effect of SCI on each evaluated outcome was assessed in three phases 
of immediate-acute (0 to 4 days after SCI), sub-acute (5 to 13 days), and chronic (14 and later). 
2.5 Statistical analyses 
Data were analyzed in STATA statistical software 14.0. Data were summarized as mean and 
standard deviation and effect size with 95% confidence interval (95% CI) was calculated using 
“metan” command. In case of the presence of heterogeneity (I2≥50% or p<0.1) random effect 
model was used and in other cases fixed-effect model was applied. The presence of publication 
bias was assessed based on Egger’s suggested method and drawing funnel plot. It should be 
noted that subgroup analysis was performed based on location of assessment (lesion site, 
rostral or caudal to injury), injury model, level of injury (cervical, thoracic and thoracolumbar), 
severity of injury, and animals’ species. Findings of subgroup analyses were reported as 
standardized mean difference (SMD) and for comparing the subgroups, odds ratio (OR) and 
95% CI were reported. Subgroup analysis was performed when the results were reported in at 
least three separate experiments. In all analyses, p<0.05 was considered as the level of 
significance. 
3 Results: 
3.1 Characteristics of included studies 
Thirty nine related articles were included involving 789 experimental animals (17-55) (Figure 
1). Twenty nine studies were performed on rats, eight on mice, one on cats, and one on monkeys. 
Models used to develop SCI were contusion in 11 studies, hemisection in nine, transection in 
seven, compression in six, crush in six, and dislocation and distraction in only one study. Thoracic 
region injury (25 papers) and cervical region (11 papers) were the most common levels of injury 
induction. Duration of follow up of the animals varies between one and 450 days (Table 2). 
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Table 1: Summary of included studies 
Authors, Year Sample size* 
control / SCI 
Gender; Species Injury model Level of 
injury 
Staining Follow up 
duration (days) 
Outcome 
Anthes et al., 1995 
(17) 
6 / 6 F; Wistar rats Compression C8-T1 Toluidine blue 1 Axon number 
Arvanian et al., 2009 
(18) 
4 / 4 F; Sprague–Dawley 
rats 
Hemisection T10 Toluidine blue 14, 42 Axon number; G-ratio 
Bretzner et al., 2008 
(19) 
NA / 7 M; Sprague–
Dawley rats 
Crush C4-C5 BDA 42 Dieback 
Busch et al., 2009 
(21) 
NA / 3 F; Sprague–Dawley 
rats 
Crush T1 Texas Red-conjugated 2, 4, 7, 14, 28 Dieback 
Busch et al., 2011 
(20)  
NA / 4 F; Sprague–Dawley 
rats 
Crush T1 Texas Red-conjugated 2, 4, 7 Dieback 
Choo et al., 2008 (22) 9 / 10 M; Sprague–
Dawley rats 
Contusion; 
dislocation; 
distraction 
C4-C5 Fluorescein-dextran and 
cascade blue-dextran 
1 Axon number 
Darlot et al., 2012 
(23) 
13 / 19 F; Sprague–Dawley 
rats 
Hemisection C2-C3 Fluorogold-fluororuby 7, 90 Axon number 
Ek et al., 2010 (24) 3 / 3 M; Sprague–
Dawley rats 
Contusion T10 Methylene blue 1, 7, 28, 70 Axon number 
Ek et al., 2012 (25) 4 / 4 NR.; Rats Contusion T10 Luxol Fast Blue 1, 7, 28, 70 Axon number 
Evans et al., 2014 
(26) 
NA / 3 M and F; 
Transgenic mice 
Crush T10 CX3CR1 GFP/+ 1, 2, 5, 8 Dieback 
Fehlings et al., 1995 
(27) 
5 / 5 F; Wistar rats Compression T1 Horseradish peroxidase 42 Axon number 
Gensel et al., 2015 
(28) 
NA / 3 F; Sprague–Dawley 
rats 
Crush C8 Texas Red-conjugated 4, 8 Dieback 
Gledhill et al., 1977 
(29) 
3 / 14 NR; Cat Compression T9-T10 NR 180 Internode length 
Guest et al., 1997 
(30) 
NA / 3 F; Wistar rats Transection T11-T12 BDA 35 Dieback 
Hesp et al., 2015 (31) 4 / 5 F; Sprague–Dawley 
rats 
Contusion T8 GFP-NF 28 Axon number; G-ratio 
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Horn et al., 2008 (32) NA / 3 F; Sprague–Dawley 
rats 
Crush C8 Texas Red-conjugated 2, 4, 7, 14, 28 G-ratio 
Houle and Jin, 2001 
(33) 
NA / 3 F; Sprague–Dawley 
rats 
Hemisection C3 BDA 7, 28, 56, 98 Dieback 
Huang et al., 2014 
(34) 
3 / 3 NR; Sprague–
Dawley rats 
Compression L1 Osmic acid staining 1, 3, 7 Axon number; G-ratio 
James et al., 2011 
(35) 
5 / 5 F; Sprague–Dawley 
rats 
Contusion T10 Eriochrome cyanine R 1, 7, 14, 28, 84, 180 Axon number; G-
ratio; velocity 
Kerschensteiner et al., 
2005 (36) 
NA / 10 NA; Transgenic 
GFP-S mice 
Transection C2-C6 GFP-labeled axon 1, 2 Dieback 
Lasiene et al., 2008 
(37) 
8 / 8 F; C57BL/6; Mice Contusion T9 BDA 56 Axon number; G-
ratio; velocity; 
Internode length 
Muradov et al., 2013 
(38) 
4 / 4 F; Sprague-Dawley 
rats 
Contusion T9 Choleratoxin B 0, 1, 2, 7 Axon number 
Nashmi and Fehlings, 
2001 (39) 
8 / 7 F; Wistar rats Compression T7 Toluidine blue 42 Axon number; G-
ratio; velocity 
Oudega et al., 1999 
(40) 
NA / 4 F; Fischer rats Transection T8 BDA 7, 14, 28, 56 Dieback 
Pallini et al., 1988 
(41) 
NA / 4 F; Wistar rats Transection T9 HRP 5, 14, 28, 56 Dieback 
Powers et al., 2012 
(42) 
3 / 18 F; Gt(ROSA)26Sor 
mice 
Contusion T9-T10 Tetramethylrhodamine 
dextran 
90 Velocity; Internode 
length 
Powers et al., 2013 
(43) 
5 / 5 F; Gt(ROSA)26Sor 
mice 
Contusion T9-T10 mG+ sheaths 30, 90, 180 Axon number; G-
ratio; Internode length 
Rosenberg and 
Wrathall, 1997 (44) 
4 / 3 F; Sprague–Dawley 
rats 
Contusion T8 Toluidine blue 1 Axon number 
Seif et al., 2007 (45) N / 5 F; Sprague–Dawley 
rats 
Hemisection T8 DiI 7, 14, 28, 56, 112 Dieback 
Siegenthaler et al., 
2007 (46) 
24 / 24 F; Sprague–Dawley 
rats 
Contusion; 
Hemisection 
T10 Resin 60 Axon number; G-ratio 
Stirling et al., 2004 
(48) 
NA / 6 NA; Wistar rats Transection C7 BDA 7, 14 Dieback 
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Stirling et al., 2013 
(47) 
NA / 7 NA; Cx3cr1 mice Transection brainstem Nile Red 1 Dieback 
Tang et al., 2015 (49) NA / 6 M; Transgenic mice Hemisection T12 Texas Red dextran 1, 2 Dieback 
Totoiu and Keirstead, 
2005 (50) 
4 / 4 F; Sprague–Dawley 
rats 
Contusion T10 Toluidine blue 7, 14, 28, 70, 120, 
450 
Axon number; G-ratio 
Wang et al., 2009 
(52) 
6 / 3 F; Sprague–Dawley 
rats 
Transection T8 NF200 0, 10, 30 Axon number 
Wang et al., 2012 
(51) 
NA / 6 F; Sprague–Dawley 
rats 
Hemisection T9 BDA 56 Dieback 
Wang et al., 2015 
(53) 
NA / 8 F; C57BL/6 mice Hemisection C5 NF200 5, 56 Dieback 
Ward et al., 2014 (54) 5 / 4 F; Sprague-Dawley 
rats 
Compression T12 NF200 and SMI31 and 
SMI32 
1, 3, 7 Axon number 
Wu et al., 2013 (55) 3 / 3 M; Macaca 
fascicularis; 
Monkey 
Hemisection T8-T9 SMI31 7, 30 Axon number 
*, number of animals per group. BDA: Biotinylated dextran amines; DiI: Dioctadecyl-tetramethyl-indocarbocyanine; GFP: Green florescent 
protein; HRP: Horseradish peroxidase; NF200: Neurofilament-200; NR: Not reported. 
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3.2 The risk of bias 
The quality assessment of included studies is presented in figure 2 and table 3. The status of 
most studies regarding bladder expression (19 studies), blinding of assessor (27 studies), 
reporting genetic background (22 studies), description of treatment allocation (32 studies) and 
description of the reasons to exclude animals from the experiment during the study (32 
studies) are at high risk of bias. The status of other items is low risk in most of the articles. Some 
degree of publication bias exists only when mean axonal retrograde degeneration (coefficient= 
-0.93; p<0.0001) and probably internode length (coefficient= 5.14; p=0.058) (Figure 2). 
 
Table 3: The quality assessment of included studies  
Author, Year  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Anthes et al., 1995 (17)  + + + + + + + + + + + ? ? ? ? 
Arvanian et al., 2009 (18)  + + + + + + + + + + + + ? ? + 
Bretzner et al., 2008 (19)  
+ + + + + + + + + + ? + + ? ? 
Busch et al., 2009 (21)  
+ + + + + + + + + + ? ? + ? ? 
Busch et al., 2011 (20)   
+ + + + + + + + + + ? ? + ? ? 
Choo et al., 2008 (22)  + + + + + + + + ? + ? + ? ? + 
Darlot et al., 2012 (23)  + + + + + + + + + + ? + ? ? + 
Ek et al., 2010 (24)  + + + + + + + + + + ? + ? ? + 
Ek et al., 2012 (25)  + + + + + + ? + + + ? ? ? ? ? 
Evans et al., 2014 (26)  
+ + + + + + + + + + ? ? + ? ? 
Fehlings et al., 1995 (27)  + + + + + + + + + ? ? + ? + ? 
Gensel et al., 2015 (28)  
+ + + + + + + + + + + ? + ? ? 
Gledhill et al., 1977 (29)  
+ + + + ? + ? + + ? ? ? ? ? ? 
Guest et al., 1997 (30)  
+ + + + + + + + + + ? ? + ? + 
Hesp et al., 2015 (31)  + + + + + + + + + + + ? ? ? ? 
Horn et al., 2008 (32)  + + + + + ? + ? + + ? ? ? ? ? 
Houle and Jin, 2001 (33)  + + + + + + + ? ? + ? ? ? ? ? 
Huang et al., 2014 (34)  + + + + + ? + + + + ? + ? + ? 
James et al., 2011 (35)  + + + + + + + ? + + + ? ? ? ? 
Kerschensteiner et al., 2005 
(36) 
 
+ + + + + + + + + + ? ? + ? ? 
Lasiene et al., 2008 (37)  
+ + + + + + + + + + + ? + ? ? 
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Muradov et al., 2013 (38)  
+ + + + + + + + + + + ? + ? ? 
Nashmi and Fehlings, 2001 
(39) 
 
+ + + + + + + + + + ? ? ? ? ? 
Oudega et al., 1999 (40)  
+ + + + + + + + + + + ? + ? ? 
Pallini et al., 1988 (41)  + + + + + + + ? ? ? + ? ? ? ? 
Powers et al., 2012 (42)  + + + + + + ? + + + ? ? ? ? ? 
Powers et al., 2013 (43)  
+ + + + + + + + + + + ? + ? ? 
Rosenberg and Wrathall, 
1997 (44) 
 
+ + + + + + + + + ? + ? ? ? ? 
Seif et al., 2007 (45)  + + + + + + + + + + + ? ? ? ? 
Siegenthaler et al., 2007 (46)  + + + + + + + ? + + + ? ? ? ? 
Stirling et al., 2004 (48)  
+ + + + + + + + + + + + + ? + 
Stirling et al., 2013 (47)  
+ + + + + + + + + + ? + + ? ? 
Tang et al., 2015 (49)  
+ + + + + + + + + + + + + + + 
Totoiu and Keirstead, 2005 
(50) 
 
+ + + + + + + ? + + + ? ? + ? 
Wang et al., 2009 (52)  + + + + + + + + + + + ? ? ? ? 
Wang et al., 2012 (51)  
+ + + + + + + + + + + ? + + ? 
Wang et al., 2015 (53)  
+ + + + + + + + + + ? ? + + ? 
Ward et al., 2014 (54)  + + + + + + + + + + + + ? ? ? 
Wu et al., 2013 (55)  + + + + + + + + + + + + + + ? 
 1. Species; 2. Using appropriate tests; 3.Severity of injury; 4.Level of injury; 5.Age/weight; 6. Number of animals 
per group; 7. Designation of strain; 8. Definition of control; 9. Description of statistical analysis; 10. Regulation 
and ethics; 11. Bladder expression; 12. Blindness of assessor; 13. Genetic background; 14. Method of allocation 
to treatments; 15. Description of the reasons to exclude animals from the experiment during the study (attrition) 
+: indicates no risk of bias; ?: the prescience of risk of bias is unclear due to insufficient descriptions in the article 
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3.3 Meta-analysis 
3.3.1 The number of axons decreases following SCI 
Analyses showed that immediately after SCI (immediate-acute phase) the total number of 
axons decreased in the lesion site of the injured spinal cord (SMD= -3.86; 95% CI: -5.02 to -
2.69). This decreasing trend continued in the sub-acute phase (SMD= -4.95; 95% CI: -6.88 to -
3.88) and reached its maximum in the chronic phase (SMD= -5.98; 95% CI: -7.56 to -4.40) (Pfor 
trend<0.0001) (figure 3). 
Subgroup analysis revealed that in the immediate-acute phase, the rate of losing axons in the 
lesion site was higher compared to 1-10 mm rostral (p<0.0001) and 1-10 mm caudal regions 
(p=0.001). In addition, the decrease of axon number in the injuries induced by the 
compression-contusion model was more evident than that in other models (p<0.0001). Yet, the 
rate of axonal degeneration was higher in severe injuries (p=0.009). 
In the sub-acute phase, it was revealed that in injuries caused by the compression-contusion 
model (p<0.05) the rate of axonal degeneration was higher than other models, while the rate 
of axonal degeneration in thoracic (p=0.21) and thoracolumbar (p=0.013) injuries was higher 
than cervical injuries. Finally, in the chronic phase, it was found that the number of degenerated 
axons in the lesion site (p<0.05) and in the thoracic level were higher than other levels (table 
4). 
3.3.2 The number of myelinated axons declines following SCI 
The findings of the meta-analysis showed that the number of myelinated axons also was altered 
after SCI. In the immediate-acute phase of SCI, the number of myelinated axons in the lesion 
site decreased significantly (SMD= -2.55; 95% CI: -3.12 to -1.98; p<0.0001). The decrease was 
many times greater in sub-acute (SMD= -4.70; 95% CI: -6.29 to -3.10; p<0.0001) and chronic 
injuries (SMD= -7.29; 95% CI: -9.67 to -4.91; p<0.0001) phases (Pfor trend<0.0001). 
The analyses performed in the immediate-acute phase showed that the number of myelinated 
axons in the lesion site was less than caudal regions of injury (p=0.01). In the sub-acute phase, 
none of the evaluated factors affected the number of myelinated axons. However, in the chronic 
phase, the myelinated axons number in the 1 to 10 mm caudal region of the injury was greater 
than the lesion site (p=0.004) (table 5). 
3.3.3 Axonal retrograde degeneration (dieback) is progressively seen after SCI 
Mean axonal retrograde degeneration in the immediate-acute phase in the rat was 461.65 µm. 
This amount was 734.07 µm and 1155.86 µm in sub-acute and chronic phases, respectively 
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(figure 3). Analyses showed that as time passed after injury, the extent of axonal retrograde 
degeneration progressively increased (Pfor trend<0.0001). 
Subgroup analysis showed that in the immediate-acute phase, the grade of axonal retrograde 
degeneration in the transection (p=0.031) model was lower than the crush model. In the sub-
acute phase, none of the factors had any effect on axonal retrograde degeneration. However, in 
the chronic injuries, the extent of axonal retrograde degeneration observed in the thoracic 
region was up to 3.58 times greater than the cervical region (p=0.002) (table 6). 
3.3.4 Myelin Sheath thickness decreases following SCI 
For assessment of the effect of SCI on myelin sheath thickness, G-ratio scale was applied. 
Analyses showed that the amount of G-ratio in the immediate-acute (SMD=4.35; 95% CI: 1.86 
to 6.85; p<0.0001), sub-acute (SMD=3.43; 95% CI: 2.26 to 4.60; p<0.0001), and chronic 
(SMD=2.01; 95% CI: 1.43 to 2.60; p<0.0001) phases were higher than in healthy animals (figure 
4). G-ratio decreased with time passed since the injury and gradually became closer to the 
measures in normal animals (Pfor trend=0.035). The data also revealed that G-ratios in severe 
injuries (p=0.04) were higher than other injury intensities (table 7).  
3.3.5 Following SCI, internode length significantly decreases 
Internode length is considered as a factor for evaluating myelination status. Following SCI, with 
the presence of oligodendrocytes at the site of injury, myelination was initiated (29, 35, 37, 42, 
43). Yet, the myelinated segments of regenerated axons were shorter than uninjured axons 
(SMD=-2.15; 95% CI: -2.68 to -1.62; p<0.0001) (figure 4).  
3.3.6 Conduction velocity of regenerated axons is less than healthy axons 
In evaluating the conduction velocity, it was shown that the conduction of neural messages in 
regenerated axons was many times slower than unaffected axons (SMD=-5.38; 95% CI: -7.40 to 
-3.36; p<0.0001). These findings are in line with the other two findings that showed both 
myelin sheath thickness and internode length decreased significantly following SCI.  
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Table 4: Subgroup analysis of total number of axon after spinal cord injury compare to intact animals 
 Effect size  Significance among subgroups 
Variable SMD (95% CI) p value Heterogeneity (p value)  Odds ratio (95% CI) p value 
Immediate and acute phase       
Overall -1.21 (-1.56 to -0.86) <0.0001 78.0% (<0.0001)  NA NA 
Location of assessment       
Lesion site -3.86 (-5.02 to -2.69) <0.0001 84.2% (<0.0001)  Ref. Ref. 
1 to 10 mm rostral -0.48 (-0.94 to -0.03) 0.037 71.0% (<0.0001)  14.41 (3.51 to 59.13) <0.0001 
 1 to 10 mm caudal -0.69 (-1.09 to -0.28) 0.001 64.7% (<0.0001)  12.57 (3.09 to 51.18) 0.001 
Injury model         
Compression-contusion -2.36 (-2.92 to -1.79) <0.0001 89.5% (<0.0001)  Ref. Ref. 
Transection 0.32 (-0.39 to 1.05) 0.374 46.5% (0.07)  14.13 (2.70 to 74.01) 0.002 
Other -0.17 (-0.47 to 0.14) 0.284 47.9% (0.013)  8.27 (2.58 to 26.45) 0.001 
Level of Injury         
Cervical -0.38 (-0.72 to -0.06) 0.022 69.2% (<0.0001)  Ref. Ref. 
Thoracic -0.64 (-1.26 to -0.01) 0.045 70.2% (<0.0001)  0.04 (0.003 to 2.00) 0.816 
Severity         
Moderate -0.35 (-0.67 to -0.03) 0.034 66.6% (<0.0001)  Ref. Ref. 
Severe -2.22 (-2.89 to -1.54) <0.0001 80.4% (<0.0001)  0.21 (0.07 to 0.68) 0.009 
Subacute phase         
Overall -2.67 (-3.37 to -1.98) <0.0001 81.9% (<0.0001)  NA NA 
Location of assessment         
Lesion site -4.95 (-6.88 to -2.02) <0.0001 78.2% (<0.0001)  Ref. Ref. 
1 to 10 mm rostral -1.88 (-2.76 to -0.99) <0.0001 82.8% (<0.0001)   12 .05 (0.90 to 
160.70) 
0.059 
1 to 10 mm caudal -2.39 (-3.50 to -1.28) <0.0001 71.2% (<0.0001)  8.28 (0.53 to 130.03) 0.128 
Injury model         
Compression-contusion -4.35 (-5.46 to -3.23) <0.0001 73.4% (0.081)  Ref. Ref. 
Hemisection -0.21 (-0.78 to 0.36) 0.470 55.5% (0.028)  32.31 (4.18 to 249.42) 0.001 
Transection -1.61 (-2.85 to -0.37) 0.011 73.9 (<0.0001)  11.41 (1.44 to 90.20) 0.022 
Level of Injury         
Cervical 0.015 (-0.21 to 0.5) 0.418 0.0% (0.817)  Ref. Ref. 
Thoracic -3.15 (-4.17 to -2.14) <0.0001 78.3% (<0.0001)  0.04 (0.003 to 0.61) 0.021 
Thoracolumbar -3.52 (-4.52 to -2.51) <0.0001 41.5% (0.081)  0.02 (0.001 to 0.41) 0.013 
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Species       
Rat -2.71 (-3.43 to -1.99) <0.0001 82.6% (<0.0001)  Ref. Ref. 
Other -2.55 (-5.8 to 0.7) 0.124 73.0% (0.025)  1.43 (0.02 to 103.04) 0.867 
Chronic phase       
Overall -3.78 (-4.56 to -3.01) <0.0001 83.3% (<0.0001)  NA NA 
Location of assessment       
Lesion site -5.98 (-7.57 to -4.40) <0.0001 76.2% (<0.0001)  Ref. Ref. 
1 to 10 mm rostral -2.48 (-3.44 to -1.51) <0.0001 80.5% (<0.0001)  17.24 (1.42 to 208.24) 0.026 
1 to 10 mm caudal -2.95 (-4.42 to -1.48) <0.0001 82.1% (<0.0001)  17.14 (1.20 to 245.41)  0.037 
Injury model       
Compression-contusion -4.76 (-5.87 to -3.65) <0.0001 81.4% (<0.0001)  Ref. Ref. 
Hemisection -1.06 (-1.98 to -0.133) 0.025 71.6% (0.001)  17.69 (0.97 to 322 .78) 0.052 
Transection -3.43 (-5.45 to -1.41) 0.001 84.2% (<0.0001)  3.31 (0.18 to 62.50) 0.416 
Level of Injury       
Cervical -0.27 (-0.69 to 0.14) 0.21 0.0% (0.726)  Ref. Ref. 
Thoracic -4.47 (-5.39 to -3.54) <0.0001 81.3% (<0.0001)  0.01 (0.0005 to 0.38) 0.012 
Severity       
Moderate -4.94 (-6.01 to -3.87) <0.0001 0.0% (0.443)  Ref. Ref. 
Severe -3.63 (-4.45 to -2.82) <0.0001 82.4% (<0.0001)  3.91 (0.11 to 134.85) 0.442 
Species       
Rat -3.69 (-4.48 to -2.91) <0.0001 83.6% (<0.0001)  Ref. Ref. 
Other -6.09 (-11.19 to -0.99) 0.019 64.1% (0.062)  6.04 (0.02 to 154.21) 0.516 
CI: Confidence interval; NA: Not applicable; SMD: Standardized mean difference. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
17 
 
Table 5: Subgroup analysis of number of myelinated axon after spinal cord injury compare to intact animals 
Variable 
Effect size  Significance among subgroups 
SMD (95% CI) p value Heterogeneity (p value)  Odds ratio (95% CI) p value 
Immediate and acute phase       
Overall -1.86 (-2.27 to -1.44) <0.0001 50.2 (<0.0001)  NA NA 
Location of assessment       
Lesion site -2.55 (-3.12 to -1.98) <0.0001 0.6% (0.440)  Ref. Ref. 
1 to 10 mm rostral -1.76 (-2.48 to -1.03) <0.0001 54.5% (0.010)  2.56 (0.93 to 7.08) 0.067 
1 to 10 mm caudal -1.33 (-1.98 to -0.67) <0.0001 51.6% (<0.0001)  3.81 (1.41 to 10.30) 0.010 
Subacute phase         
Overall -3.32 (-4.12 to -2.52) <0.0001 65.4% (<0.0001)  NA NA 
Location of assessment         
Lesion site -4.70 (-6.29 to -3.10) <0.0001 54.8% (0.024)  Ref. Ref. 
1 to 10 mm rostral -3.52 (-4.42 to -2.64) <0.0001 9.9% (0.353)   1.78 (0.22 to 14.43) 0.576 
1 to 10 mm caudal -1.87 (-2.99 to -0.75) 0.001 66.8% (0.002)  12.63 (1.76 to 90.72) 0.128 
Level of Injury         
Thoracic -4.63 (-6.32 to -2.94) <0.0001 77.6% (<0.0001)  Ref. Ref. 
Thoracolumbar -2.57 (-3.23 to -1.90) <0.0001 28.7% (0.156)  0.27 (0.04 to 1.88) 0.18 
Chronic phase       
Overall -5.00 (-6.25 to -3.74) <0.0001 82.5% (<0.0001)  NA NA 
Location of assessment       
Lesion site -7.98 (-9.50 to -4.91) <0.0001 81.4% (<0.0001)  Ref. Ref. 
1 to 10 mm rostral -4.73 (-6.45 to -3.01) <0.0001 63.3% (0.004)  6.91 (0.26 to 184.98) 0.239 
1 to 10 mm caudal -2.20 (-4.22 to -0.17) 0.034 84.6% (<0.0001)  128.16 (5.28 to 310.48)  0.004 
Severity       
Moderate -7.06 (-8.98 to -5.14) <0.0001 0.0% (0.705)  Ref. Ref. 
Severe -4.91 (-6.29 to -3.53) <0.0001 81.9% (<0.0001)  0.01 (0.0001 to 5.90) 0.115 
CI: Confidence interval; NA: Not applicable; SMD: Standardized mean difference. AC
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Table 6: Subgroup analysis of mean axonal retrograde degeneration (dieback) after spinal cord injury in rat model 
Variable 
Effect size  Significance among subgroups 
Mean* (95% CI) p value Heterogeneity (p value)  Odds ratio (95% CI) p value 
Immediate and acute 
phase 
      
Overall 461.65 (348.93 to 574.37) <0.0001 92.8% (<0.0001)  NA NA 
Injury model         
Crush 501.87 (411.69 to 592.05) <0.0001 84.9% (<0.0001)  Ref. Ref. 
Transection 181.00 (102.60 to 259.40) <0.0001 0.0% (>0.99)  0.85 (0.74 to 0.98) 0.031 
Level of Injury         
Cervical 504.64 (338.16 to 671.12) <0.0001 91.1% (<0.0001)  Ref. Ref. 
Thoracic 434.20 (289.79 to 578.60) <0.0001 91.0% (<0.0001)  0.93 (0.70 to 1.24) 0.570 
Subacute phase         
Overall 734.07 (585.01 to 883.13) <0.0001 96.0% (<0.0001)  NA NA 
Injury model         
Crush 667.96 (623.99 to 711.93) <0.0001 0.0% (0.929)  Ref. Ref. 
Hemisection 896.08 (332.19 to 1459.98) 0.002 93.9% (<0.0001)  1.27 (0.79 to 2.06) 0.300 
Transection 709.35 (438.30 to 980.40) <0.0001 97.7% (<0.0001)  1.06 (0.70 to 1.62) 0.785 
Level of Injury         
Cervical 644.63 (581.52 to 707.74) <0.0001 9.0% (0.359)  Ref. Ref. 
Thoracic 820.72 (611.64 to 1029.81) <0.0001 97.2% (<0.0001)  1.28 (0.89 to 1.86) 0.172 
Chronic phase       
Overall 1155.86 (853.58 to 1715.43) <0.0001 96.7% (<0.0001)  NA NA 
Injury model       
Crush 960.54 (547.28 to 1373.81) <0.0001 75.2% (0.018)  Ref. Ref. 
Hemisection 1284.51 (853.58 to 1715.43) <0.0001 94.3% (<0.0001)  1.34 (0.30 to 5.94) 0.685 
Transection 1096.90 (613.89 to 1579.91) <0.0001 98.4% (<0.0001)  1.07 (0.22 to 5.34) 0.929 
Level of Injury       
Cervical 573.55 (438.29 to 708.81) <0.0001 56.9% (0.010)  Ref. Ref. 
Thoracic 1885.10 (1413.53 to 2356.66) <0.0001 95.7% (<0.0001)  3.58 (1.70 to 7.52) 0.002 
*, Data are presented as micrometer (µm); CI: Confidence interval; NA: Not applicable. 
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Table 7: Subgroup analysis of mean G-ratio after spinal cord injury  
Variable Effect size  Significance among subgroups 
SMD (95% CI) p value Heterogeneity (p value)  Odds ratio (95% CI) p value 
Chronic phase       
Overall 2.01 (1.43 to 2.60) <0.0001 82.0% (<0.0001)  NA NA 
Severity       
Moderate 1.56 (0.92 to 2.19) <0.0001 65.6% (<0.0001)  Ref. Ref 
Severe 3.05 (1.99 to 4.1) <0.0001 66.7% (<0.0001)  4.37 (1.08 to 17.73) 0.040 
Species       
Rat 2.56 (1.94 to 3.18) <0.0001 62.4% (<0.0001)  Ref. Ref. 
Mice 0.32 (-0.21 to 0.85) 0.231 0.0% (0.957)  0.12 (0.4 to 0.36)  0.001 
CI: Confidence interval; NA: Not applicable; SMD: Standardized mean difference. 
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4 Discussion: 
A quantitative analysis was performed on axonal pathophysiology and the changes in myelin 
sheath following SCI. The results indicate that the number of axons and myelin structure 
changes after SCI. The number of axons (both total number of axons and myelinated axons) 
progressively decreases after SCI and remaining axons also gradually show retrograde 
degeneration, the highest rate of which is seen in the chronic phase of SCI. Regarding myelin, 
findings varied a little. After SCI, myelin sheath thickness decreased but in the chronic phase of 
injury, remyelination was induced and myelinated sheath reappeared around the axons 
gradually. However, thickness and length of this regenerated myelin were smaller than intact 
axons, leading to functional abnormalities. The evidence for this claim was the decrease in axon 
conduction velocity after SCI in the chronic phase. Table 8 depicts the most important findings 
of the present study in various phases of injury. 
After SCI, degeneration of axon is observed and gradually exacerbates. The decrease of the 
axons number as well as significant axonal retrograde degeneration can be seen. However, 
regeneration of injured axons or sprouting of spared fibers is limited due to the presence of 
numerous endogenous barriers. For example, after SCI, nociception receptors such as ORL1 
and Nogo receptors show an up-regulation, which is a preventive factor in axon growth (56, 
57). Additionally, other inhibitory molecules related to myelin such as MAG, OMgp, and CSPGs 
are intensively expressed, which delay the axon regrowth after SCI (58). Among cellular factors, 
the presence of astrocytes, fibroblasts, microglia, macrophages, and other immune cells at the 
site of injury can be pointed out. The role of each of these mechanisms in SCI is under debate. 
For example, the presence of astrocytes at the site of injury and its adjacent tissues were 
reported to have a beneficial role for axon growth (59); some other studies showed that it could 
lead to the intensification of gliosis and inflammatory responses and delay in recovery (60, 61). 
Similar differences were also reported regarding the presence of microglia (62). Overall, it is 
likely that the factors restricting growth and axon elongation overweighed the factors inducing 
axonal regeneration (57).  
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Table 8: Summary of pathophysiological changes in axon and myelin after spinal cord injury according to injury phase. 
Phase Change
s 
Injury model Level of injury Severity of injury Species 
Immediate and acute       
1- Total number of axons ⇓ Compression-contusion 
injury caused highest axon 
lost 
Axon numbers is lower in 
thoracolumbar injuries  
Axon numbers is lower 
in severe injuries 
No data 
2- Number of myelinated 
axons 
⇓ No data No data No data No data 
3- Occurrence of dieback ⇑ Dieback in crush model of 
SCI is significantly higher 
Level of injury has not any 
effect 
No data Dieback in mice 
is lower than rat 
4- Myelin sheet thickness ⇓⇓⇓?? No data No data No data No data 
5- Internode length of myelin ??? No data No data No data No data 
6- Axonal conduction velocity ⇓⇓⇓?? No data No data No data No data 
Subacute phase      
1- Total number of axons ⇓⇓ Total number of axons is 
lower in hemisection and 
transection models 
Total number of axons is 
lower in thoracic and 
thoracolumbar injuries 
No data 
 
The animal 
species has not 
any effect axons 
after SCI  
2- Number of myelinated 
axons 
⇓⇓ No data Total number of myelinated 
axons did not differ in 
thoracic and thoracolumbar 
injuries. There is not data for 
cervical injuries 
No data No data 
 
3- Occurrence of dieback ⇑⇑ No data Level of injury has not any 
effect 
No data No data 
4- Myelin sheet thickness ⇓⇓ No data No data No data No data 
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5- Internode length of myelin ???? No data No data No data No data 
6- Axonal conduction velocity ⇓⇓?? No data No data No data No data 
Chronic phase      
1- Total number of axons ⇓⇓⇓ Injury model has not any 
effect 
Total number of axons is 
lower in thoracic injuries 
Severity of injury has 
not any effect 
The animal 
species has not 
any effect 
2- Number of myelinated 
axons 
⇓⇓⇓ Injury model has not any 
effect 
No data Severity of injury has 
not any effect 
No data 
3- Occurrence of dieback ⇑⇑⇑ Injury model has not any 
effect 
Mean dieback is higher in 
thoracic injuries 
No data No data 
4- Myelin sheet thickness ⇓ No data No data Myelin sheet is thinner 
in severe injuries 
No data 
5- Internode length of myelin ⇓⇓ No data No data No data No data 
6- Axonal conduction velocity ⇓ No data No data No data No data 
⇓, Decrease. 
⇓?: Decrease but there is not enough data. 
⇑: Increase. 
???: There is not enough data. 
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The point that was determined in subgroup analysis was the role of SCI model on the number 
of axons and retrograde axonal degeneration. In the immediate-acute phase, the rate of neuron 
degeneration in the injuries caused by compression-contusion (crash model for retrograde 
axonal degeneration) was more than other models. However, in the chronic phase, the injury 
model did not affect the number of axons and dieback. In injuries caused by transection or 
hemisection, only focal tissue damage with less apoptosis, demyelination, and extension of 
injury were reported as well as less inflammation process (63, 64). However, inflammation, 
apoptosis and cellular damage are more severe in the contusion/compression models than the 
hemisection/transection models. In the compression/contusion model, a larger area would be 
affected due to the width of the clip or diameter of the weight drop apparatus. Also, an initial 
compression force lead to the immediate necrosis. However, in the transection model, there is 
no compression force, only the incision of the cord disturb the integrity of the axons and vessels 
in the transected area triggering the secondary injury at a later time. Thus, greater axonal loss 
in the contusion/compression model is expected. Therefore, some researchers believe that 
transection is not a proper model for evaluating tissue damage following SCI (63).  
Among other factors affecting the axons number and degeneration following SCI is the level of 
injury. The rate of axon degeneration in thoracic injuries was reported to be higher than 
cervical injuries. In addition, it was found that mean retrograde degeneration of axons in the 
thoracic region was up to 3.5 times more than the cervical region injuries. The reason for this 
difference is not known and further studies are needed. However, studies show that in cervical 
region injuries, more recovery is observed compared to thoracic region injuries (65-69), which 
might be due to the number of live and active axons being present in cervical regions following 
injury. 
Demyelination following SCI is a result of the rapid death of oligodendrocytes. Numerous 
studies are available to show that express apoptosis of oligodendrocytes following SCI is closely 
associated with demyelination (24, 25, 34, 38). In the chronic phase of SCI, oligodendrogenesis 
is seen when remyelination occurs (31, 52, 54). This compensation mechanism leads to a 
decrease in myelin debris and reduction in the number of degenerated myelin but the measures 
of these pathologies do not ever return to the normal level (25, 50). It is likely that myelin 
synthesized after SCI has both shorter length and smaller thickness compared to intact myelin, 
probably due to the difference in the mechanism of myelin synthesis between the periods of 
prenatal development and adulthood. Myelin synthesized at fetal life is able to become up to 40 
times thicker and longer, while myelin synthesized in adulthood is shorter and thinner. In fetal 
life, the ratio of the oligodendrocytes to axons number is 1:1, while in adulthood this ratio 
reaches about 1:60. Therefore, it is likely that the decrease of oligodendrocytes in adulthood 
may explain the demyelination following SCI (70). This shortening of the space between two 
Ranvier nodes as well as myelin diameter becoming thinner is associated with changes in 
myelin function. Therefore, the conduction velocity in remyelinated axons is slower than intact 
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axons. There is evidence that shows axon conduction velocity decreases progressively with an 
increase of remyelinated segment numbers in the axon (71) and this decrease is even greater 
than the rate estimated in theoretical models.  
There is still controversy regarding the extent to which pathologic changes are in line with the 
recovery observed after SCI. For example, Li et al. showed that nerve regeneration at the site of 
injury did not have an effect on recovery following SCI, the recovery observed was mostly due 
to the changes occurring in the caudal regions of injury (72). In addition, Jack et al. showed that 
the locomotion outcome of the animals under treatment becomes worse after electrical 
stimulation of the corticospinal tract, which was reported to promote significant axonal 
collateralization (73). However, two other studies show that axonal outgrow, following the use 
of electrical stimulation, is associated with improvement in locomotion after SCI (74, 75).  It is 
likely that treatment interventions that don’t independently result in axonal regeneration 
cannot lead to a significant improvement in motor function recovery and might even make it 
worse; because without the use of rehabilitation training program, proper synapse connections 
are not formed and this will lead to delay in recovery (73). These axonal collaterals may even 
intensify pain pathways in incomplete injuries and lead to neuropathic pain (76, 77). 
The thoracic spinal cord and the cervical spinal cord may respond to the injury differently. In 
this systematic review, we found that the level of injury could affect the pathophysiology of SCI. 
one reason may be the distance of the axotomized location to the cell soma. For example, the 
nucleus of the supraspinal neurons are found in the brainstem and the axons pass the cord to 
the thoracic level. In addition, propriospinal neurons, which are intrinsic neurons of the spinal 
cord, could be divided into two groups: a) the short thoracic propriospinal (TPS) neurons are 
located in the thoracic level and their axons project rostrally or caudally for a few levels. b) The 
long projection propriospinal neurons include long ascending propriospinal tract (LAPT) 
neurons and long descending propriospinal tract (LDPT) neurons. The LAPT neurons are found 
in the lumbosacral enlargement that projects rostrally to the cervical enlargement, whereas the 
LDPT neuros are found in the cervical enlargement projecting mainly caudally to the 
lumbosacral enlargement. Therefore, there is a heterogeneity along the cord based on the type 
of the neurons and the length of the axons. Based on our previous systematic review on the fate 
of neurons after traumatic spinal cord injury in the rats (78), the propriospinal neurons have 
differential vulnerabilities to the contusion injury. The TPS neurons present an apoptotic 
response during the acute phase, but the LDPT neurons do not undergo apoptosis for at least 
one month. Therefore, the difference in the extent of axon degeneration after the cervical and 
the thoracic injury may be attributed to the cord heterogeneity. 
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One of the most common methods of measuring the status of myelin in the injured spinal cord 
is evaluating the volume of the myelinated area using myelin-specific staining such as Luxol 
fast blue staining or evaluating the expression of myelin sheath proteins such as basic myelin 
protein (56, 80). In the present study, the volume of the myelinated area was not evaluated 
since it would not provide the opportunity for assessing the rate of normal and regenerated 
myelin. Another limitation of the present study is the limited number of studies included in the 
section evaluating internode length and conduction velocity, which prevented subgroup 
analysis in this section. In addition, the risk of bias classification based on the quality of the 
studies was not feasible when there is no defined cut-off point. Moreover, interpretation of the 
findings in pre-clinical studies was not performed since there is no accurate definition of the 
level of evidence. 
4.1 Conclusion: 
Findings of the present meta-analysis indicated the difference in the pathophysiology of axons 
and myelin sheath in various phases of SCI. This difference in the structure of axons and myelin 
also leads to functional changes such as the decrease in conduction velocity. There is a higher 
rate of degeneration of axon and myelin in compression-contusion model, severe injuries, and 
thoracic injuries. In addition, there are still significant disagreements on the correlation 
between motor function recovery following SCI and axon regeneration. Further studies are 
needed to address whether the structural changes in the axons or other factors following SCI 
lead to motor and sensory functional recovery. 
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Figure legends 
Figure 1: PRISMA flow diagram of present meta-analysis 
 
Figure 2: The risk of bias in assessed outcomes. Item 1. Species; Item 2. Using appropriate tests; Item 
3.Severity of injury; Item 4.Level of injury; Item 5.Age/weight; Item 6. Number of animals per group; 
Item 7. Designation of strain; Item 8. Definition of control; Item 9. Description of statistical analysis; 
Item 10. Regulation and ethics; Item 11. Bladder expression; Item 12. Blindness of assessor; Item 13. 
Genetic background; Item 14. Method of allocation to treatments; Item 15. Description of the reasons to 
exclude animals from the experiment during the study (attrition). 
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Figure 3: Pathophysiological changes of axons after spinal cord injury. Mean retrograde axonal degeneration 
is presented in rat. CI: Confidence interval; SMD: Standardized mean difference.  
 
Figure 4: Myelin Pathophysiological changes after spinal cord injury. CI: Confidence interval; SMD: 
Standardized mean difference. 
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